Toth Financial Advisory Corp Purchases 5,905 Shares of DexCom, Inc. (NASDAQ:DXCM)

Toth Financial Advisory Corp raised its position in DexCom, Inc. (NASDAQ:DXCM) by 870.9% during the first quarter, Holdings Channel reports. The fund owned 6,583 shares of the medical device company’s stock after acquiring an additional 5,905 shares during the period. Toth Financial Advisory Corp’s holdings in DexCom were worth $913,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC lifted its holdings in DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the period. CX Institutional bought a new position in DexCom in the fourth quarter valued at about $286,000. Bank of New Hampshire purchased a new stake in DexCom in the first quarter worth about $1,508,000. abrdn plc increased its position in DexCom by 21.1% in the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after buying an additional 66,348 shares in the last quarter. Finally, Cerity Partners LLC increased its position in DexCom by 5,791.0% in the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after buying an additional 456,097 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Raymond James upped their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Finally, Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.33.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the sale, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,735 shares of company stock valued at $7,619,347. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $113.38 on Friday. The stock has a 50 day moving average of $123.14 and a 200 day moving average of $125.70. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The firm has a market cap of $45.09 billion, a PE ratio of 73.15, a PEG ratio of 2.77 and a beta of 1.22. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. On average, research analysts expect that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.